Symptomatic and functional remission in European patients with schizophrenia after paliperidone palmitate treatment (1-month and 3-month formulations)

被引：0
|
作者：
Savitz, A. [1 ]
Xu, H. [2 ]
Gopal, S. [1 ]
Nuamah, I. [2 ]
Hough, D. [1 ]
Hargarter, L. [3 ]
机构：
[1] Janssen Res & Dev, Cent Nervous Syst, Titusville, FL USA
[2] Janssen Res & Dev, Clin Biostats NJ, Titusville, FL USA
[3] Janssen Cilag, Med & Sci Affairs, Neuss, Germany
来源：
EUROPEAN NEUROPSYCHOPHARMACOLOGY | 2016年 / 26卷
关键词：
D O I：
10.1016/S0924-977X(16)31590-5
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P.3.d.029
引用
收藏
页码：S546 / S547
页数：2
相关论文
共 50 条
  • [21] Healthcare resource use of paliperidone palmitate 3-month injection vs. paliperidone palmitate 1-month injection: An analysis of phase III clinical trial hospital data
    Woodruff, K.
    Chirila, C.
    Zheng, Q.
    Van Impe, K.
    Nuamah, I.
    EUROPEAN PSYCHIATRY, 2016, 33 : S265 - S266
  • [22] COST-EFFECTIVENESS ANALYSIS OF THE PALIPERIDONE PALMITATE 3-MONTH FORMULATION VERSUS 1-MONTH FORMULATION FROM A HEALTHCARE PAYER PERSPECTIVE
    Arikan, Y.
    Koral, S.
    Baris, H.
    Malhan, S.
    Oksuz, E.
    VALUE IN HEALTH, 2017, 20 (09) : A713 - A713
  • [23] Paliperidone 3-Month Injection for Treatment of Schizophrenia: A Narrative Review
    Edinoff, Amber N.
    Doppalapudi, Prithvi K.
    Orellana, Claudia
    Ochoa, Caroline
    Patti, Shelby
    Ghaffar, Yahya
    Cornett, Elyse M.
    Kaye, Aaron J.
    Viswanath, Omar
    Urits, Ivan
    Kaye, Adam M.
    Kaye, Alan D.
    FRONTIERS IN PSYCHIATRY, 2021, 12
  • [24] Improvement of Negative Symptoms in Schizophrenia with Paliperidone Palmitate 1-Month and 3-Month Long-Acting Injectables: Results from a Phase 3 Non-Inferiority Study
    Gopal, Srihari
    Gogate, Jagadish
    Pungor, Katalin
    Kim, Edward
    Singh, Arun
    Mathews, Maju
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2020, 16 : 681 - 690
  • [25] Effect of Paliperidone Palmitate 3-Month Formulation on Goal Attainment and Disability After 52 Weeks' Treatment in Patients with Clinically Stable Schizophrenia
    Lambert, Martin
    Sanchez, Pedro
    Bergmans, Paul
    Gopal, Srihari
    Mathews, Maju
    Wooller, Annette
    Pungor, Katalin
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2020, 16 : 3197 - 3208
  • [26] TREATMENT PERSISTENCE OF PALIPERIDONE PALMITATE 3-MONTH IN PATIENTS WITH SCHIZOPHRENIA -AN ANALYSIS OF JAPAN MEDICAL DATA CENTER CLAIMS DATABASE
    Chinen, Madoka
    Saga, Yosuke
    Horio, Hiroshi
    Chiang, Chih-Lin
    Wakamatsu, Akihide
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2025, 28 : i163 - i163
  • [27] Symptomatic Remission and Functional Recovery after Paliperidone Palmitate 3-monthly or 1-monthly treatment in Asian Patients with Exacerbated Schizophrenia
    Savitz, Adam
    Xu, Haiyan
    Gopal, Srihari
    Nuamah, Isaac
    Hough, David
    Mathews, Maju
    Feng, Yu
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2016, 19 : 242 - 243
  • [28] Paliperidone palmitate 3-month formulation and sexual dysfunction in young schizophrenic patients
    Plasencia Garcia De Diego, B. O.
    Romero Guillena, S. L.
    Gotor Sanchez-Luengo, F.
    EUROPEAN PSYCHIATRY, 2019, 56 : S261 - S261
  • [29] Paliperidone Palmitate (3-Month Formulation) Administered once Quarterly Prevents Relapse in Latin American Patients with Schizophrenia
    Savitz, Adam
    Xu, Haiyan
    Gopal, Sri
    Nuamah, Isaac
    Mathews, Maju
    Soares, Bernardo
    BIOLOGICAL PSYCHIATRY, 2017, 81 (10) : S211 - S211
  • [30] INTERIM REPORT OF A POST-MARKETING SURVEILLANCE OF PALIPERIDONE PALMITATE 3-MONTH FORMULATION IN JAPANESE PATIENTS WITH SCHIZOPHRENIA
    Marumoto, Tatsuro
    Saga, Yosuke
    Kinoshita, Hiroaki
    Morita, Natsuko
    Touma, Tokiko
    Wakamatsu, Shinya
    Takebe, Kyoko
    Wakamatsu, Akihide
    Chiang, Chih-Lin
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2025, 28 : i160 - i160
12345